Syneos Health and Elligo Announce Strategic Collaboration
Syneos Health, a biopharmaceutical solutions organization, including CRO services, and Elligo Health Research, a provider of clinical research services to physician practices, are entering a strategic collaboration. Syneos Health will collaborate with Elligo to pilot new ways of quickly finding patients to enlist them in clinical trial research. Elligo’s platform identifies patients for clinical trials using electronic health records and then provides their physicians with the infrastructure to conduct the research in their own practices. The collaboration will seek to build a centrally managed infrastructure and regulatory research system, which could include deploying expert staff and providing the training and regulatory guidance needed to run a trial, removing physician burden.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
